AzTrials
AzTrials

C.Surgical ProcedurePhase 4SICSNCT02798068

Steroids and Microcirculation In Cardiac Surgery

A Phase 4 study of C.Surgical Procedure and Cardiac, run by Erasme University Hospital at 1 site in Belgium.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Cardiac surgery is sometimes associated with organ dysfunction of variable severity (renal insufficiency, cognitive decline, arrhythmias, ARDS). The phenomenon responsible is an intense inflammatory reaction induced by cardiopulmonary bypass, leading to microcirculation alterations, specially in endothelial cell and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
C.Surgical Procedure, Cardiac
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteBelgium
Study dates
May 2016to Sep 2021
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients eligible for cardiac surgery

Who cannot join

  • Age under 18years
  • Allergy to corticoids
  • Extreme emergency surgery
  • Upper member vascular disease

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Hôpital Erasme

    Brussels, 1070

Other trials in Belgium

About this study

Official title: Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1)

Cardiac surgery is sometimes associated with organ dysfunction of variable severity (renal insufficiency, cognitive decline, arrhythmias, ARDS). The phenomenon responsible is an intense inflammatory reaction induced by cardiopulmonary bypass, leading to microcirculation alterations, specially in endothelial cell and its protective layer - glycocalyx. Endothelial dysfunction then reduces the reactivity of peripheral tissues to hypoxia, and is associated with bad prognosis.

High - dose corticoids administration at anesthesia induction in cardiac surgery could attenuate the intensity of this inflammatory reaction, and represents the current practice in our hospital. Nevertheless, this attitude is abandoned in numerous cardiac surgery centres.

Read the detailed description

Introduction Cardiac surgery is associated with variable severity organ dysfunction, which further leads to an increase of ICU length of stay (ICU LOS) or even higher mortality. Various mecanisms enter into account, from global through regional hemodynamics until microcirculation alterations.

These are due to an intense inflammatory reaction triggered by the contact of blood with cardiopulmonary bypass surfaces, the contact blood - air from cardiotomy aspiration, heparin and heparin - protamin complexes, ischemia - reperfusion mediators, and toxins from the digestive tube.

These alterations are observed in both the beating heart surgery and surgery with cardiopulmonary bypass (CBP). The inflammatory response is probably less important in off - pump surgery though this is hypothesis often questionned and some publications show that the changes associated with CBP could only be transient.

Inflammatory response is possibly reduced by high - dose corticoid administration at anesthesia induction - by preserving cell membrane integrity, leucocyte adhesion and cellular immunity attenuation, and finally by complement and cytokine release reduction.

Numerous metaanalyses show benefits of this strategy with an acceptable security profile:

  • Atrial fibrillation reduction
  • Possible ICU LOS reduction
  • Same incidence of wound infection

Within the risks can be observed:

  • Higher incidence of hyperglycemia
  • No impact on overall mortality However, two recent big RCTs did not find any benefit as in terms of morbidity-mortality, incidence of wound infection and possibly an increase in number of reinterventions for tamponnade.

Providing the low level of evidence on real benefits and some of the secondary effects, the systematic use of corticoids (as applied in our centre) was abandonned by a some of cardiac surgery centres.

Nevertheless, corticoids could be beneficial in specific subgroups. In order to identify these patients, it is important to understand the mecanism of microcirculation alterations in the setting of cardiac surgery with CBP and the effect of corticoids on CBP induced inflammatory processes.

The alterations of endothelial function under CBP may be observed at three levels :

  1. endothelial reactivity (vasodilation et vasoconstriction)
  2. blood flow (acceleration et deceleration)
  3. glycocalyx (endothelial protective layer) These three components of microcirculation are tightly linked. De Backer study on sublingual microcirculation shows its alterations specific for this type of surgery (more pronounced in cardiac surgery with CBP than off-pump) and not found in minor surgery (thyroidectomy). He also found a positive correlation with lactate level. Cardiac surgery can be considered as an interesting microcirculation and endothelial function study model.

The hypothesis of investigators is that microcirculation modifications along with those of endothelial function in cardiac surgery with CBP are due to endothelial cell impairement and impairement of its protective layer - glycocalyx, condition which deregulates the peripheral tissue reactivity to hypoxia, and that corticoids could reduce these alterations.

The investigators will study the endothelial function by three methods :

A/ FMD (Flow Mediated vasoDilation) which is a non invasive technique considered as the gold standard for endothelial reactivity evaluation since the end of 1990s. It is based on echographic measurement of brachial artery diameter variation and the Doppler flow evaluation, during an episode of transient ischemia induced by pneumatic cuff inflation (vascular occlusion test).

Three studies showed a reversible alteration of endothelial function mainly after cardiac surgery using CBP with continuous blood flow (FMD variation of about 11%). Expecting a reduction of endothelial dysfunction with corticoids by 5%, the investigators will analyze a group of 60 patients (30 in the corticoids group and 30 in the placebo group). In previous studies, variation is already significative when FMD varies from 1,5 - 2%.

B/ NIRS (near infrared spectroscopy) - it's a non invasive technique which measures peripheral tissue oxygen saturation and allows to assess oxygen consumption and microcirculation reactivity during an arterial occlusion test distally to compressive cuff.

Alterations of the variables derived from delta StO2 (peripheral tissue oxygen saturation) after an ischemic - reperfusion event, rather than absolute value of StO2 are predictive of bad prognosis in a septic patient or in severe head injury. These variables are delta StO2, HbT (total tissue hemoglobin) and THI (muscular hemoglobin index). From these elements can be calculated others: RdecStO2 (StO2 decrease rate during ischemic event reflecting the tissue oxygen consumption) and RincStO2 (increase rate of StO2 during the reperfusion phase, corresponding to relative hyperemia). Both are expressed in %/s. The intensity of reperfusion can be quantified by delta THI.

A recent study in cardiac surgery did not show StO2 modifications under CBP but providing a small population sample and the type of monitoring used, this study might include some methodologic biais.

Finally, very recently a correlation between FMD and the variation of NIRS during a vascular occlusion test has been found in a young healthy subject, which only confirms the influence of endothelial function onto microcirculation.

C/ Syndecan - 1 concentration assessment: This molecule is closely linked to glycocalyx and is considered as the most predictive marker of its integrity.

Many factors might cause lesions of this structure (inflammation, hyperglycemia, CBP, etc). Its destruction causes further an impairement of endothelial function (vasoconstriction et vasodilation), mediated principally by endothelial factors.

Corticoids can be considered as the most effective molecule for glycocalyx protection.

Yet the investigators will analyze syndecan - 1 as a glycocalyx marker.

Material and methods :

After ethics commitee approbation and signed informed consent obtention, the investigators will enroll 60 patients scheduled for cardiac surgery with CBP (aorto - coronary bypass graft or valve replacement).

Patients randomized in the Corticoids group will receive 500mg of methylprednisolone in 100ml of NaCl 0,9% at anesthesia induction, Placebo group will receive 100ml of NaCl 0,9% - both solutions are prepared at the hospital pharmacy and only the pharmacist knows the preparation content (double blinding).

Exclusion criteria are age under 18, extreme emergency surgery if the testing would slow down the surgical treatment. The investigators also exclude the patients where the placement of pneumatic cuff would be impossible (amputation, AV fistula)

Anesthesia procedure:

All the patients receive the same anesthesia technique, based on propofol and remifentanil at objective of concentration. Relaxation is achieved by cisatracurium in continuous infusion. This type of anesthesia is the current practice in Erasme hospital. All the patients are equipped with radial artery catheter and central venous catheter, the use of pulmonary artery catheter is left to anesthetist's discretion.

Before starting the CBP, all patients receive heparin with target ACT (activated clotting time) above 480seconds. The priming of CBP consists on 500ml of gelatin (Geloplasma, Fresenius), with 500ml of cristaloids (Plasmalyte, Baxter) and 200ml of mannitol (Mannitol 15%, Baxter). Cardioplegy is achieved by blood infusion (T 36°) with potassium chloride. The CBP flow is continuous of 2.4L/m2 and mean arterial pressure is maintened between 60 and 90 mm Hg. Glycemia is controlled strictly from the moment of anesthesia induction by short acting insulin administrered continuously.

All patients are transferred to ICU after the surgery, sedated with propofol and remifentanyl until hemodynamic stability and absence of bleeding is achieved. Sedation is then stopped and patient is extubated.

Vascular occlusion test:

Arterial diameter variation and Doppler flow are measured at brachial artery above medial epicondyl, proximally to the pneumatic cuff placed at forearm. For echography analysis, a linear probe of 12 MHz will be used, held by a metallic support to allow more precision and better reproducibility. After initial diameter measurement, pneumatic cuff 50 mmHg will be inflated above the arterial pressure of the patient during 5minutes, in order to induce ischemia. Diameter variations in brachial artery are measured continuously from 30 secondes before releasing of the cuff until 3 minutes afterwards. FMD is evaluated by following parameters : baseline diameter and maximal FMD variation in pourcents. In numerous studies, FMD is calculated using the formula: FMD (%) = ([diametre of maximal dilation after cuff release - baseline diametre]/ baseline diametre) x 100. In order to reduce variability of the measrure, diameter variation will be adjusted to baseline diameter and to initiating stimulus assessed by Doppler flow. Data will be stocked and analyzed by Quipu FMD.

StO2 is measured by tissular spectrometer (Invos, Covidien) consisting of a photodetector, processor and a 15 mm optic probe. This proble is placed over thenar eminence of the arm without any IV line. StO2 is enregistered every 2 secondes.

Practically, after performing the initial echographic measurements, and after 3 minutes of stabilisation of StO2 (baseline), an ischemic event of 5 minutes is created by a fast pneumatic cuff inflation to a value of 50mmHg above patients systemic blood pressure. This will stop arterial and venous blood flow in the forearm, leading to a decrease of HbO2 (= rate of decrease StO2 (%/s)).

After 5 minutes the cuff will be rapidly deflated (<1seconds) inducing arterial diameter and flow increase - the variation is assessed by echography and Doppler. At the same time, StO2 increases (= StO2 increase rate (%/s)) and achieves higher values than baseline (= reactive hyperemia = delta diametre, flow velocity and StO2). The NIRS device measures also THi (tissular hemoglobin index) at baseline and 1 minute, its minimum et maximum.

The increase rate of arterial diameter reflects endothelial reactivity while StO2 increase rate is considered as a tissue = hemoglobin flow marker. Reactive hyperemia can be interpreted as a test of microcirculation reactivity. Rate of StO2 decrease/THi is considered as oxygen consumption marker.

Syndecan-1 analysis is performed on frozen plasma by ELISA technique, using specific antibodies (ELISA kit from Ray Biotech, Inc), this method has already been used in previous studies.

Timing of measurements:

Measures are performed on the day before surgery, at the ICU admission, at 24h and at the day 7 of hospital stay.

Glycocalyx function assessment:

The first analysis will be performed on the day before surgery, then after anesthesia induction, at ICU admission, at 24h and 48h.

Being tested
Solu-medrol or placebo administration
Keywords
Steroids, Cardiac surgery, Endothelial dysfunction, Glycocalyx, Flow mediated vasodilation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Solu-medrol or placebo administrationDrug

    Also called Solu-medrol 500mg IV BE145214, Solu-medrol 500mg IV H02AB04, Solu-medrol 500mg IV SUB14562MIG, Solu-medrol 500mg IV 277S102F12

    patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction

Study groups in NCT02798068
Study groupRoleWhat they receive
Solu - MedrolActive comparatorSolu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
Receives: Drug: Solu-medrol or placebo administration
PlaceboPlacebo comparatorNaCl 0,9% 100ml IV once single administration
Receives: Drug: Solu-medrol or placebo administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Flow Mediated Vasodilation change

    Arterial diameter variation and Doppler flow are measured at brachial artery during vascular occlusion test - viariation of diameter and doppler flow befor and after cuff release will be assessed

    Measured: 3 measurements of 5 minutes each - vascular occlusion test once daily during 48h.

Secondary outcomes (1)
  1. StO2 variation change

    Tissue oxygen saturation will be assessed by near - infrared spectroscopy (physiological parameter assesment based on spectrophotometry) during vascular occlusion test and after cuff release

    Measured: 4 measurements of 5 minutes each - vascular occlusion test test once daily during 48h

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jun 2016 (estimated)
  2. Study startMay 2016
  3. Primary completionSep 2021
  4. Study completionSep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02798068
Sponsor's protocol ID
P2016/017
Acronym
SICS
Status last verified
Sep 2021
First submitted
25 May 2016
Last updated
1 Jul 2024
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Patila T, Kukkonen S, Vento A, Pettila V, Suojaranta-Ylinen R. Relation of the Sequential Organ Failure Assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg. 2006 Dec;82(6):2072-8. doi: 10.1016/j.athoracsur.2006.06.025.

    PubMed 17126112
  • Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997 Sep;112(3):676-92. doi: 10.1378/chest.112.3.676.

    PubMed 9315800
  • Riddington DW, Venkatesh B, Boivin CM, Bonser RS, Elliott TS, Marshall T, Mountford PJ, Bion JF. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA. 1996 Apr 3;275(13):1007-12.

    PubMed 8596232
  • Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg. 1998 Feb;65(2):420-4. doi: 10.1016/s0003-4975(97)01127-2.

    PubMed 9485239
  • Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):384-93. doi: 10.1053/j.jvca.2008.09.007. Epub 2008 Dec 3. No abstract available.

    PubMed 19054695
  • Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J. 2008 Nov;29(21):2592-600. doi: 10.1093/eurheartj/ehn333. Epub 2008 Jul 28.

    PubMed 18664462
  • Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth. 2011 Feb;25(1):156-65. doi: 10.1053/j.jvca.2010.03.015. Epub 2010 May 26.

    PubMed 20537923
  • Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum A, Quantz M, Tagarakis GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S; SIRS Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Sep 26;386(10000):1243-1253. doi: 10.1016/S0140-6736(15)00273-1.

    PubMed 26460660
  • van Osch D, Dieleman JM, Nathoe HM, Boasson MP, Kluin J, Bunge JJ, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, de Lange F, Boer C, van Dijk D; Dexamethasone for Cardiac Surgery Study Group. Intraoperative High-Dose Dexamethasone in Cardiac Surgery and the Risk of Rethoracotomy. Ann Thorac Surg. 2015 Dec;100(6):2237-42. doi: 10.1016/j.athoracsur.2015.06.025. Epub 2015 Aug 25.

    PubMed 26319483
  • De Backer D, Dubois MJ, Schmartz D, Koch M, Ducart A, Barvais L, Vincent JL. Microcirculatory alterations in cardiac surgery: effects of cardiopulmonary bypass and anesthesia. Ann Thorac Surg. 2009 Nov;88(5):1396-403. doi: 10.1016/j.athoracsur.2009.07.002.

    PubMed 19853081
  • Alley H, Owens CD, Gasper WJ, Grenon SM. Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. J Vis Exp. 2014 Oct 22;(92):e52070. doi: 10.3791/52070.

    PubMed 25406739
  • Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. doi: 10.1016/s0735-1097(01)01746-6.

    PubMed 11788217
  • Sangalli F, Guazzi M, Senni S, Sala W, Caruso R, Costa MC, Formica F, Avalli L, Fumagalli R. Assessing Endothelial Responsiveness After Cardiopulmonary Bypass: Insights on Different Perfusion Modalities. J Cardiothorac Vasc Anesth. 2015 Aug;29(4):912-6. doi: 10.1053/j.jvca.2014.11.008. Epub 2014 Nov 11.

    PubMed 25661644
  • De Backer D, Durand A. Monitoring the microcirculation in critically ill patients. Best Pract Res Clin Anaesthesiol. 2014 Dec;28(4):441-51. doi: 10.1016/j.bpa.2014.09.005. Epub 2014 Sep 28.

    PubMed 25480773
  • Cohn SM, Nathens AB, Moore FA, Rhee P, Puyana JC, Moore EE, Beilman GJ; StO2 in Trauma Patients Trial Investigators. Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation. J Trauma. 2007 Jan;62(1):44-54; discussion 54-5. doi: 10.1097/TA.0b013e31802eb817.

    PubMed 17215732

Questions about this trial

What is this clinical trial studying?

A Phase 4 study of C.Surgical Procedure and Cardiac, run by Erasme University Hospital at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early. Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Flow Mediated Vasodilation change (time frame: 3 measurements of 5 minutes each - vascular occlusion test once daily during 48h.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02798068, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in